



VGYAAN Pharmaceuticals Receives US FDA Approval for Leuprolide Acetate Injection, 14 mg/ 2.8 mL (1 mg/0.2 mL) Multi-Dose Vials, the Generic Equivalent to LUPRON®

August 13, 2021

Skillman, NJ -- VGYAAN Pharmaceuticals today announced that it has received final US FDA approval for Leuprolide Acetate Injection, 14 mg/2.8 mL (1 mg/0.2 mL) Multi-Dose Vials, the generic equivalent to LUPRON®.

Leuprolide Acetate Injection is indicated in the palliative treatment of advanced prostatic cancer.

"We are truly humbled and proud of this approval given the complexity of the product and the considerable regulatory requirements, as well as the fact that it is a combination product. It has been a long and arduous process to reach this significant milestone as we had to overcome multiple challenges along the way. This approval is a true testament to VGYAAN's capabilities and our collaborative business model," commented Nailesh Bhatt, Chief Executive Officer of VGYAAN Pharmaceuticals.

Nimisha Bhatt, Chief Operating Officer of VGYAAN Pharmaceuticals added, "This fourth product approval adds an injectable drug to VGYAAN's growing portfolio in our quest to provide high quality and affordable generic drugs to patients. This drug has experienced significant supply chain disruptions and shortages over the last few years, leading to high prices and quality issues. Therefore, we are especially looking forward to working with our valuable customers and channel partners to launch Leuprolide Acetate in the near future so we can help mitigate pain points."

About VGYAAN Pharmaceuticals

VGYAAN Pharmaceuticals LLC, headquartered in Skillman, New Jersey is focused on developing and commercializing clinically critical drugs. VGYAAN is fully equipped and licensed to perform sales, marketing, and distribution of high quality and affordable drugs in the US with capabilities to serve clients across a wide range of channels. Our product portfolio includes solid orals and injectables in a broad range of therapeutic areas.

For more information, please visit www.vgyaan.com or contact media@vgyaan.com.

LUPRON® is a registered trademark of AbbVie, Inc.